Among currently available vaccine strategies for cancer, nucleotide-based vaccination is an appealing treatment modality.
Curevacs' mRNA containing vaccines (RNActive®) combine the beneficial properties of sufficient antigen-expression, autologous immune-stimulation and a high flexibility with respect to production and application. CV9103 and CV9104 are novel RNActive®-derived anticancer vaccines for the treatment of patients with prostate cancer. After successful phase I/II studies with documentation of good tolerability and favorable immune-activation of CV9103, the vaccine CV9104 is currently undergoing clinical testing in specific clinical settings such as castration resistant prostate cancer and as a neoadjuvant agent in men with high risk prostate cancer prior to surgery. This review discusses the available preclinical and clinical data on the anticancer vaccination treatment with RNActive®-derived anticancer-vaccines CV9103 and CV9104.
Written by:
Rausch S, Schwentner C, Stenzl A, Bedke J. Are you the author?
Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany; German Cancer Consortium (DKTK); Partnerstandort Tübingen; German Cancer Research Center (DKFZ); Heidelberg, Germany.
Reference: Hum Vaccin Immunother. 2014 Jul 7;10(11).
doi: 10.4161/hv.29553
PubMed Abstract
PMID: 24999635
UroToday.com Prostate Cancer Immunotherapy Section
